Arch Biopartners has engaged Dalton Pharma Services to perform the good manufacturing practice (GMP) campaign for Metablok, (LSALT peptide), the company’s drug candidate for preventing acute kidney injury. Dalton will be responsible for the GMP preparation and filling of Metablok into glass vials through to the release of a clinical drug product. The clinical drug product will then form part of the intravenous kits that will be used to support the Phase I human trial to evaluate Metablo...